Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations

Women's Health

Volumn 5, Issue 1, 2009, Pages 63-68

  Metcalfe, Kelly A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

BRCA1; BRCA2; Breast cancer; Prophylactic salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; GENE MUTATION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; MASTECTOMY; MENOPAUSAL SYNDROME; OVARIECTOMY; OVARY CANCER; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SALPINGOOOPHORECTOMY; SEXUAL DYSFUNCTION; SOCIAL PSYCHOLOGY; THERAPY EFFECT;

ADULT; AGE FACTORS; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MENOPAUSE, PREMATURE; MIDDLE AGED; OVARIECTOMY; RISK FACTORS;

EID: 59349095468     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.5.1.63     Document Type: Review

References (28)

1. Antoniou A, Pharoah PD, Narod S et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72(5), 1117-1130 (2003).
2. Lakhani SR, Van De Vijver MJ, Jacquemier J et al.: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 20(9), 2310-2318 (2002).
3. Foulkes WD, Metcalfe K, Sun P et al.: Estrogen receptor status in BRCA1 and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin. Cancer Res. 10(6), 2029-2034 (2004).
4. Hartmann LC, Schaid JD, Woods JE et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340(2), 77-85 (1999).
5. Hartmann LC, Sellers TA, Schaid DJ et al.: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl Cancer Inst. 93(21), 1633-1637 (2001).
6. Eisen A, Lubinski J, Klijn J et al.: Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J. Clin. Oncol. 23(30), 7491-7496 (2005).
7. Kauff ND, Domchek SM, Friebel TM et al.: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J. Clin. Oncol. 26(8), 1331-1337 (2008).
8. Rebbeck TR, Lynch HT, Neuhausen SL et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346(21), 1616-1622 (2002).
9. King MC, Wieand S, Hale K et al.: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18), 2251-225(2001).
10. Zweemer RP, van Diest PJ, Verheijen RH et al.: Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol. Oncol. 76(1), 45-50 (2000).
11. Schubert EL, Lee MK, Mefford HC et al.: BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am. J. Hum. Genet. 60(5), 1031-1040 (1997).
12. McEwen AR, McConnell DT, Kenwright DN, Gaskell DJ, Cherry A, Kidd AM: Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy. Gynecol. Oncol. 92(3), 992-994 (2004).
13. Rose PG, Shrigley R, Wiesner GL: Germlin BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. Gynecol. Oncol. 77(2), 319-320 (2000).
14. Finch A, Beiner M, Lubinski J et al.: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296(2), 185-192 (2006).
15. Kauff ND, Satagopan JM, Robson ME et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346(21), 1609-1615 (2002).
16. Metcalfe K, Lynch HT, Ghadirian P et al.: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 22(12), 2328-2335 (2004).
17. Metcalfe KA, Ghadirian P, Rosen B et al.: Variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers across Canada. Open Med. 1(2), E92-E98 (2007).
18. Bradbury AR, Ibe CN, Dignam JJ et al.: Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet. Med. 10(3) 161-166 (2008).
19. Laki F, Kirova YM, This P et al.: Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer 109(9), 1784-179 (2007).
20. Madalinska JB, van Beurden M, Bleiker EM et al.: Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers. J. Clin. Oncol. 25(3), 301-307 (2007).
21. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J et al.: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 122(9), 2017-2022 (2008).
22. Metcalfe KA, Foulkes WD, Kim-Sing C et al.: Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin. Genet. 73(5), 474-479 (2008).
23. Uyei A, Peterson SK, Erlichman J et al.: Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer 107(12), 2745-2751 (2006).
24. Eisen A, Lubinski J, Gronwald J et al.: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J. Natl Cancer Inst. 100(19), 1361-1367 (2008).
25. Elit L, Esplen MJ, Butler K, Narod S: Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam. Cancer 1(3-4), 149-156 (2001).
26. Madalinska JB, Hollenstein J, Bleiker E et al.: Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J. Clin. Oncol. 23(28), 6890-6898 (2005).
27. Tiller K, Meiser B, Butow P et al.: Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study. Gynecol. Oncol. 86(2), 212-219 (2002).
28. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH: Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J. Clin. Oncol. 23(34), 8629-8635 (2005).